Trial reportBritish journal of clinical pharmacology2014
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.
Trial report in British journal of clinical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmaco Kinetic and Pharmacokinetic-Pharmacodynamic Variability of Infliximab
Characterization of Immunogenicity of Tumor Necrosis Factor Inhibitors in Arthritis Patients With Poorer Treatment Response Due to Gender, Obesity and Smoking Status.
Who cites it
50 citing papers in PubMed, 81 citations in OpenAlex.
- Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID-19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV-1 IM).Journal of clinical pharmacology · 2025Trial
- Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects.Clinical pharmacology in drug development · 2020Trial
- Trial
- Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.Journal of Crohn's & colitis · 2017Trial
- Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.British journal of clinical pharmacology · 2016Trial
- A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients.British journal of clinical pharmacology · 2015Trial
- Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- The effect of tumor necrosis factor-alpha on rheumatoid arthritis-related pain: overview of evidence and mechanistic pathways.Croatian medical journal · 2026Review
- A mathematical model to simulate the biological action of Infliximab on TNF-Bulletin of mathematical biology · 2026Article
- Article
- Pharmacokinetic Characterization of Rituximab in Patients with Glomerular Diseases.Therapeutic drug monitoring · 2025Article
- Targeting rheumatoid arthritis: a molecular perspective on biologic therapies and clinical progress.Journal of biological engineering · 2025Review
- Prediction of Monoclonal Antibody Pharmacokinetics in Pediatric Populations Using PBPK Modeling and Simulation.Pharmaceutics · 2025Article
- Pharmacogenomics of TNF inhibitors.Frontiers in immunology · 2025Review
- [Sex-specific aspects in rheumatology].Zeitschrift fur Rheumatologie · 2024Article
- [Gender-specific differences in the diagnosis and treatment of inflammatory rheumatic diseases].Innere Medizin (Heidelberg, Germany) · 2023Review
- Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and RemicadeAdvances in therapy · 2023Article
- Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus.Journal of clinical pharmacology · 2022Article
- Pharmacokinetics of Haloperidol in Critically Ill Patients: Is There an Association with Inflammation?Pharmaceutics · 2022Article
- Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model.Clinical pharmacokinetics · 2022Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsInfliximab, an anti-tumour necrosis factor-α monoclonal antibody, is indicated in rheumatoid arthritis (RA). Our objective was to evaluate the influence of the sources of infliximab pharmacokinetic variability in RA.
methodsEighty-four patients treated with infliximab for RA were included in a prospective noncomparative study. They were analysed between two consecutive infliximab infusions. Infliximab concentrations were measured before the infusion, 2 h, 1 and 4 weeks after the infusion and immediately before the next infusion. Infliximab concentrations were described using a two-compartment population pharmacokinetic model.
resultsThe mean (interindividual standard deviation) estimated central volume of distribution was 2.3 l (36%) and systemic clearance was 0.019 l h(-1) (37%). The central volume of distribution increased with bodyweight; it was doubled between 50 and 90 kg. Systemic clearance increased with pre-infusion C-reactive protein concentration by 20%, varying from 3 to 14 mg l(-) 1, and was decreased by 30% when methotrexate was coadministered.
conclusionsThe influence of methotrexate and inflammation on infliximab clearance suggests that individual adjustment of infliximab doses according to disease activity may be useful in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.